Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID-19: Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE Study

NCT04361903 is registered in ClinicalTrials.gov with Azienda USL Toscana Nord Ovest as lead sponsor.

NCT NCT04361903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04361903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID-19: Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE Study
Lead sponsor
Azienda USL Toscana Nord Ovest
Phase
Observational
Overall status
Unknown status
Start date
April 25, 2020
Completion date
May 31, 2020
Enrollment
13 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

severe acute respiratory syndrome coronavirus 2